Smith & Nephew (SNN) senior manager sells 17,643 shares at £14.25

Rhea-AI Filing Summary

Smith & Nephew plc filed a report disclosing a share transaction by a senior manager under UK Market Abuse Regulation. Vasant Padmanabhan, President Research & Development ENT and classified as a person discharging managerial responsibilities, carried out a sale of 17,643 Smith & Nephew ordinary shares on 9 September 2025. The shares have a nominal value of USD 0.20 each, and the transaction price recorded in the disclosure was £14.25 per share. The grant was noted as taking place outside a trading venue, and the disclosure was signed on behalf of the company by the Company Secretary.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under the

Securities Exchange Act of 1934

September 09, 2025

Commission File Number 001-14978

SMITH & NEPHEW plc

(Registrant’s name)

Building 5, Croxley Park, Hatters Lane

Watford, England, WD18 8YE

 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ✓         Form 40-F __

SMITH & NEPHEW PLC

9 September 2025

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

Reason for the notification
Initial notification /Amendment	Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name	Smith & Nephew plc
LEI	213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument	Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code	ISIN: GB0009223206
Nature of the transaction	Sale of ordinary shares
Date of Transaction	2025 - 09 - 09
Place of Transaction	Grant took place outside the trading venue

Name (Position)	Director / PDMR	Price (£)	Volume	Aggregated information
Vasant Padmanabhan (President Research & Development ENT)	PDMR	14.25	17,643	N/A Single Transaction

Philip Horner

Group Deputy Company Secretary

Smith & Nephew plc

Tel:  +44 (0)1923 477100

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Smith & Nephew plc
		(Registrant)
Date: September 09, 2025	By:	/s/ Helen Barraclough
		Helen Barraclough
		Company Secretary

FAQ

What insider transaction did Smith & Nephew (SNN) report in this 6-K?

The company reported a sale of 17,643 Smith & Nephew plc ordinary shares by a senior manager, disclosed as a transaction by a person discharging managerial responsibilities.

Who at Smith & Nephew (SNN) sold shares and what is their role?

The seller was Vasant Padmanabhan, identified as a Person Discharging Managerial Responsibilities (PDMR) and holding the position of President Research & Development ENT.

At what price were the Smith & Nephew (SNN) shares sold?

The disclosed transaction price was £14.25 per Smith & Nephew plc ordinary share.

When did the Smith & Nephew (SNN) insider share sale take place?

The transaction date disclosed for the sale of ordinary shares was 9 September 2025.

What type of shares were involved in the Smith & Nephew (SNN) transaction?

The transaction involved Smith & Nephew plc ordinary shares with a nominal value of USD 0.20 each, identified by ISIN GB0009223206.

Under which regulation was this Smith & Nephew (SNN) transaction disclosed?

The transaction was disclosed in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of UK law).